Oxford BioMedica Board Change

RNS Number : 9950X
Oxford Biomedica PLC
12 May 2016
 

 

 

 

 

 

 

Oxford BioMedica Board Change

 

 

 

Oxford, UK - 12 May 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today announces that Dr Paul Blake will leave the Group when his current contract expires at the end of August 2016. Dr Blake was appointed to Oxford BioMedica's Board as a non-executive Director in January 2010 and subsequently he became Chief Development Officer in September 2014.

 

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "Paul has made a significant contribution to Oxford BioMedica in both his non-executive and executive capacities. I thank Paul for his contribution to the development and continued success of Oxford BioMedica and wish him the best for his future."

 

 

-Ends-

 

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Financial and corporate communications enquiries:

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton

 

 

 

Tel: +44 (0)20 3709 5700

 

 

 

Notes for editors

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEANSFFFEKEFF
UK 100

Latest directors dealings